Drug Name Clavamox

Indications: hay fever, bronchial asthma (preferably local application of analogues with high presystemic elimination, e. g. , beclomethasone, budesonide); anaphylactic shock (i. v. in high dosage)—a probably nongenomic action of immediate onset. Definition: a recurrent, episodic shortness of breath caused by bronchoconstriction arising from airway inflammation and hyperreactivity.
It is the drug of choice in the treatment of angina pectoris attacks. For this purpose, it is administered as a spray, or in sublingual or buccal tablets for transmucosal delivery. The onset of action is between 1 and 3 min. Due to a nearly complete presystemic elimination, it is poorly suited for oral administration.

 

B-lymphocytes “recognize” antigen surface structures by means of membrane receptors that resemble the antibodies formed subsequently. T-lymphocytes (naive B-cells) require the antigen to be presented on the surface of macrophages or other cells in conjunction with the major histocompatibility complex (MHC); the latter permits recognition of antigenic structures by means of the T-cell receptor.
Ergotamine, as well as the ergotoxine alkaloids (ergocristine, ergocryptine, ergocornine), have a predominantly vascular action. Depending on the initial caliber, constriction or dilation may be elicited. The mechanism of action is unclear; a mixed antagonism at ?- adrenoceptors and agonism at 5-HT-receptors may be important. Ergotamine is used in the treatment of migraine.